Picture of Oncolytics Biotech logo

ONC — Oncolytics Biotech Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+0.87%
3m-24.82%
6m-13.8%
1yr-59.37%
Volume Change (%)
10d/3m-65.27%
Price vs... (%)
52w High-62.54%
50d MA-10.43%
200d MA-36.26%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-63.41%
Return on Equity-66.88%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Oncolytics Biotech EPS forecast chart

Profile Summary

Oncolytics Biotech Inc. is a biotechnology company, which is engaged in developing pelareorep, an intravenously delivered immunotherapeutic agent. The Company is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
April 2nd, 1998
Public Since
June 1st, 2000
No. of Employees
26
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconToronto Stock Exchange
Shares in Issue
57,634,432

ONC Share Price Performance

Upcoming Events for ONC

Q2 2022 Oncolytics Biotech Inc Earnings Release

Q3 2022 Oncolytics Biotech Inc Earnings Release

Similar to ONC

Picture of AEterna Zentaris logo

AEterna Zentaris

ca flag iconToronto Stock Exchange

Picture of Antibe Therapeutics logo

Antibe Therapeutics

ca flag iconToronto Stock Exchange

Picture of Appili Therapeutics logo

Appili Therapeutics

ca flag iconToronto Stock Exchange

Picture of Aptose Biosciences logo

Aptose Biosciences

ca flag iconToronto Stock Exchange

Picture of Avicanna logo

Avicanna

ca flag iconToronto Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email